Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : Previous years symbols : AMRX save search
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 4.72%
H: 0.0%
C: 0.0%
fda opioid approval treatment for spray
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: -1.08%
H: 1.09%
C: -0.55%
rtu first
Amneal to Report First Quarter 2024 Results on May 3, 2024
Published: 2024-04-10 (Crawled : 13:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: -0.52%
H: 3.86%
C: 0.0%
first report results
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 0.0%
H: 0.33%
C: -2.64%
fda approval
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
Published: 2024-02-27 (Crawled : 14:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: -1.89%
H: 1.75%
C: 0.0%
ipx203 biotech agreement
Amneal to Participate at Upcoming Investor Conference
Published: 2024-02-13 (Crawled : 13:30) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: -3.84%
H: 2.57%
C: -0.45%
conference
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
Published: 2024-02-08 (Crawled : 21:00) - globenewswire.com
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 0.18%
H: 1.83%
C: 1.83%
ipx203 drug resubmission application response
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
Published: 2024-02-07 (Crawled : 11:00) - prnewswire.com
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -4.29%
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
|
| O: 2.49%
H: 0.97%
C: -2.91%
business agreement china
Deb Autor, Former FDA Deputy Commissioner, Appointed CEO of Healthcare Innovation Catalysts
Published: 2024-02-01 (Crawled : 13:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 2.8%
H: 0.55%
C: 0.18%
fda ceo innovation
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
Published: 2024-01-25 (Crawled : 12:30) - globenewswire.com
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 1.57%
H: 0.73%
C: -0.82%
ipx203 license pharmaceuticals therapeutics agreement
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
Published: 2024-01-10 (Crawled : 14:30) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 0.0%
H: 0.7%
C: -3.16%
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2023-12-21 (Crawled : 16:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 1.13%
H: 3.83%
C: 3.55%
conference
Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance
Published: 2023-10-23 (Crawled : 22:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: -1.44%
H: 3.51%
C: -1.75%
year financial results
Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio
Published: 2023-10-12 (Crawled : 14:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 0.24%
H: 0.95%
C: -9.74%
Amneal to Report Third Quarter 2023 Results on November 7, 2023
Published: 2023-10-05 (Crawled : 12:30) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 0.71%
H: 0.95%
C: -7.8%
report results
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
Published: 2023-09-06 (Crawled : 22:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 3.14%
H: 0.0%
C: -6.09%
fda approval injection
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
Published: 2023-09-06 (Crawled : 14:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 3.14%
H: 0.0%
C: -6.09%
fda approval
Amneal to Participate at the 2023 Wells Fargo Healthcare Conference
Published: 2023-08-25 (Crawled : 18:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -3.69%
conference
JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease
Published: 2023-08-24 (Crawled : 22:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 0.49%
H: 0.36%
C: -1.95%
ipx203 disease parkinson’s results study
Generic Drugs Market is Projected To Reach USD 835.7 Billion By 2032, Growing at A CAGR of 8.1% | Valuates Reports
Published: 2023-08-09 (Crawled : 14:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 1.92%
H: 0.0%
C: 0.0%
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 0.1%
H: 1.33%
C: -1.12%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.14%
H: 0.8%
C: 0.43%
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 0.0%
H: 0.67%
C: -5.58%
reach growing market
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.